By METAvivor Advocacy Team
As the legislative landscape in Washington D.C. shifts to meet the demands of the 2026 fiscal year, METAvivor remains at the forefront of the fight for metastatic breast cancer (MBC) patients. February has been a month of intense activity, marked by the launch of the third annual GroundSwell Advocacy Event and critical progress in federal funding negotiations. This report details the strategic maneuvers, legislative milestones, and collaborative efforts currently underway to ensure that the voices of those living with MBC are not only heard but acted upon in the halls of Congress.
I. The Federal Funding Landscape: A Mixed Picture of Progress and Stagnation
The month began with a significant win for the medical research community. On February 3, the signing of the Consolidated Appropriations Act of 2026 signaled a commitment to sustained federal investment in health. The package includes vital funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Centers for Disease Control and Prevention’s (CDC) Division of Cancer Prevention and Control. Perhaps most notably, the Department of Defense (DOD) Congressionally Directed Medical Research Program (CDMRP) Breast Cancer program received $145 million—a $15 million increase over the Fiscal Year 2025 levels. This victory is a testament to the persistent pressure applied by patient advocates, including those within the One Voice Against Cancer (OVAC) coalition.
The DHS Stalemate
While research funding saw a positive trajectory, the broader legislative environment remains fractured. The Department of Homeland Security (DHS) currently faces a funding shortfall. Following a missed deadline on February 13, the federal government has been forced to manage a partial shutdown of specific DHS-affiliated entities, including the Coast Guard, the TSA, and the Secret Service. While this stalemate creates administrative friction, it is important to note that Immigration and Customs Enforcement (ICE)—a focal point of the current political contention—remains funded via earlier legislative maneuvers, effectively insulating that agency from the current impasse.
Looking Toward FY2027
Despite the lingering DHS issues, the wheels of the FY2027 appropriations process are already turning. With the FY2026 bills largely finalized, Congress is shifting its attention to the next cycle. METAvivor, in partnership with the AdHoc Group on Healthcare Funding and OVAC, has begun submitting unified funding requests. This collective approach is designed to amplify the resonance of our advocacy, ensuring that the unique needs of the MBC community are prioritized as legislators begin their internal deliberations for the upcoming year.
II. GroundSwell: A Digital Force for Legislative Advocacy
The cornerstone of METAvivor’s February efforts is the third annual GroundSwell Virtual Advocacy Event. Launched on February 23 and running through March 6, this initiative represents a technological and strategic pivot in how patient advocates engage with their representatives.
Training the Frontlines
Recognizing that effective advocacy requires preparation, METAvivor invested heavily in educational infrastructure for the more than 100 participants involved in this year’s event. By hosting specialized training webinars and dedicated sessions for State Captains, we have ensured that our advocates are equipped with more than just passion; they are armed with data, scripts, and nuanced policy insights.
The toolkit provided to these advocates is comprehensive, including:
- Targeted Fact Sheets: Distilling complex MBC data into accessible talking points.
- Communication Scripts: Draft emails and meeting templates for both initial contact and follow-up.
- Legislative Mapping: A detailed, state-by-state directory linking advocates directly to the healthcare staff of their specific Members of Congress.
This virtual format has democratized the advocacy experience, allowing patients who are physically unable to travel to Washington to maintain a consistent and powerful presence on Capitol Hill. The feedback mechanism, powered by a post-meeting survey, will allow METAvivor to track the success of these meetings and identify specific congressional offices requiring further education or persistent follow-up.
III. Legislative Priorities: Tracking the Bills
METAvivor’s legislative agenda for 2026 is anchored by two primary pieces of legislation that aim to remove the systemic barriers faced by MBC patients.
The Metastatic Breast Cancer Access to Care Act (H.R. 2048)
This bill remains our primary legislative priority. As of late February, H.R. 2048 has achieved significant momentum, boasting 214 cosponsors—a critical milestone. The bipartisan nature of this support is particularly encouraging, with 154 Democrats and 60 Republicans currently signed on. The Senate companion bill, S. 3442, has also seen growth, now carrying 5 cosponsors. These numbers reflect a growing recognition among lawmakers that the current waiting periods for Social Security Disability Insurance (SSDI) and Medicare are life-threatening hurdles for MBC patients.
The Cancer Drug Parity Act
The Cancer Drug Parity Act continues to gain traction in the House, with 26 cosponsors. METAvivor is currently working to secure a path for re-introduction in the Senate, viewing this as a necessary step to address the financial toxicity and disparities in access to oral chemotherapy.
IV. Strategic Initiatives: Data and Modernization
Beyond immediate legislative lobbying, METAvivor is focusing on a long-term strategic initiative: the modernization of the NCI’s SEER (Surveillance, Epidemiology, and End Results) Cancer Registry.
Bridging the Data Gap
For too long, the SEER registry has failed to accurately reflect the reality of living with metastatic disease. By failing to capture the full spectrum of MBC patient outcomes, the current data creates an incomplete picture of the epidemic. In February, METAvivor met with the North American Association of Central Cancer Registries (NAACCR) to initiate a collaborative roadmap for reform.
Our goal is to ensure that future registries account for the nuance of metastatic progression, which will in turn drive more accurate research funding and better public health policy. By aligning with the Alliance for Breast Cancer Policy, we are elevating this issue to the national stage, advocating for a level of data transparency that is commensurate with the urgency of the MBC crisis.
V. Organizational Evolution: Strengthening the Infrastructure
Effective advocacy is not merely about the message; it is about the medium. METAvivor is currently undergoing an audit of its internal advocacy tools. Following successful demonstration calls with digital advocacy platforms like Voter Voice, the organization is evaluating how best to modernize our grassroots and grasstops engagement systems.
The objective is twofold:
- Reduce Friction: Make it easier for the average patient to contact their legislator with minimal technological barrier.
- Streamline Intelligence: Improve the way METAvivor staff manages the data generated from thousands of interactions with Congressional offices.
This infrastructure upgrade will ensure that as we look toward the Thriving Together: 2026 Conference on Metastatic Breast Cancer, we have the analytical capability to turn event participation into actionable legislative support.
VI. Looking Ahead: The Path Forward
As we transition into March, the focus remains on closing the loop on GroundSwell meetings and intensifying the push for FY2027 appropriations. The legislative window is narrow, and the stakes for the MBC community are perpetually high.
The success of these initiatives relies on the sustained commitment of our advocate network. By bridging the gap between clinical research, legislative policy, and patient experience, METAvivor is not just asking for change—we are designing it.
Key Objectives for the Coming Weeks:
- Post-GroundSwell Follow-up: Ensuring that every meeting conducted by our advocates translates into a tangible legislative commitment from their representatives.
- Senate Strategy: Advancing the Cancer Drug Parity Act through renewed discussions with Senate leadership.
- SEER Advocacy: Finalizing our policy document regarding the modernization of cancer registries to present to the NCI and other relevant stakeholders.
The journey toward comprehensive care and a cure for metastatic breast cancer is a marathon, not a sprint. With the dedication shown by our community in February, we are better positioned than ever to influence the legislative outcomes that will define the future of MBC treatment and support.
Sincerely,
The METAvivor Advocacy Team
About the Author
